论文部分内容阅读
目的:检测75例卵巢上皮性肿瘤中TGF-β1和CD44v6的表达情况,探讨二者在卵巢癌的诊断及预后中的意义。方法:采用免疫组织化学方法检测正常及上皮性卵巢肿瘤组织中TGF-β1和CD44v6的水平。结果:①TGF-β1和CD44v6在恶性卵巢上皮性肿瘤中表达阳性率分别为30.5%和22.5%,TGF-β1在卵巢癌中的表达低于卵巢瘤及正常卵巢(P<0.05),而CD44v6在卵巢癌中的表达较高(P<0.05)。②卵巢癌晚期、有腹水或淋巴结转移组TGF-β1和CD44v6表达阳性率组间比较有显著性差异(P<0.05),二者呈完全相反的趋势,CD44v6在黏液性癌中的表达高于浆液性癌(P<0.05)。③TGF-β1和CD44v6在卵巢癌中无复合阳性表达。结论:TGF-β1表达降低预示肿瘤恶性卵巢上皮性肿瘤期别较晚预后较差,Cd44v6可能作为上皮性卵巢癌的分子标志物。
OBJECTIVE: To detect the expression of TGF-β1 and CD44v6 in 75 cases of ovarian epithelial neoplasm and to explore their significance in the diagnosis and prognosis of ovarian cancer. Methods: Immunohistochemistry was used to detect the levels of TGF-β1 and CD44v6 in normal and epithelial ovarian tumor tissues. The positive rates of TGF-β1 and CD44v6 in malignant ovarian epithelial tumor were 30.5% and 22.5%, respectively. The expression of TGF-β1 in ovarian cancer was lower than that in ovarian cancer and normal ovary (P <0.05), while CD44v6 was Ovarian cancer was higher (P <0.05). ②The positive rate of TGF-β1 and CD44v6 expression in ascites or lymph node metastasis was significantly different between the two groups (P <0.05), the two showed a completely opposite trend, the expression of CD44v6 in mucinous carcinoma was higher than Serous cancer (P <0.05). ③ TGF-β1 and CD44v6 in ovarian cancer without complex positive expression. CONCLUSION: The decreased expression of TGF-β1 indicates that the prognosis of malignant ovarian epithelial neoplasms is poor late. Cd44v6 may be used as a molecular marker for epithelial ovarian cancer.